AstraZeneca’s Brilinta (ticagrelor) Receives the US FDA’s Priority Review for Reducing Stroke in Patients with Acute Ischemic Stroke or Transient Ischemic Attack

 AstraZeneca’s Brilinta (ticagrelor) Receives the US FDA’s Priority Review for Reducing Stroke in Patients with Acute Ischemic Stroke or Transient Ischemic Attack

AstraZeneca’s Brilinta (ticagrelor) Receives the US FDA’s Priority Review for Reducing Stroke in Patients with Acute Ischemic Stroke or Transient Ischemic Attack

Shots:

  • The US FDA has accepted sNDA and granted PR for Brilinta to reduce subsequent stroke in patients experiencing an acute ischemic stroke or TIA. The sNDA is based on P-III THALES study assessing Brilinta (90mg, bid, for 30 days) + aspirin vs aspirin as monothx. in 11,000 patients with non-cardioembolic acute ischaemic stroke or high-risk TIA
  • The study resulted in a reduction in the risk of the primary composite endpoint of stroke and death while the safety is consistent with the known profile of the therapy. The anticipated PDUFA date is in Q4’20
  • Brilinta (ticagrelor) is an oral, reversible, direct-acting P2Y12 receptor antagonist acts by inhibiting platelet activation. The therapy when co-administered with aspirin prevents atherothrombotic events in adult patients with ACS, or for patients with a history of MI and a high risk of developing an atherothrombotic event

Click here to read full press release/ article | Ref: AstraZeneca | Image: New York Post

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post